This technology is a monoclonal antibody therapy to treat acute myeloid leukemia, myelodysplastic syndrome, and hematological myeloid malignancies and relapses.
The standard of care for acute myeloid leukemia (AML) has not changed for over five decades, and 60-80% of patients relapse despite complete remission. Current chemotherapies are solely targeting leukemic cells, which are prone to developing resistance. Therefore, this type of treatment often fails in relapse cases. Current therapies do not address the bone marrow niche, where the serum amyloid A1 (SAA1) molecule contributes to disease progression.
This technology describes the development of an anti-serum amyloid A1 (SAA1) antibody, which targets and inhibits SAA1, a key protein involved in leukemia progression. SAA1 is elevated in the bone marrow microenvironment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), where it contributes to leukemia cell survival and proliferation. The antibody specifically binds to SAA1, blocking its proliferative effects on leukemia cells and potentially reducing leukemia progression and relapse. This approach offers a novel treatment strategy targeting the bone marrow niche rather than the cancer cells directly, addressing a critical gap in current therapies.
This technology has been validated in vitro.
Patent Pending (WO/2025/038794)
IR CU22360, CU24038, CU24039, CU24044
Licensing Contact: Jerry Kokoshka
